Skip to main content
WHANIN PHARM CO.,LTD logo

WHANIN PHARM CO.,LTD — Investor Relations & Filings

Ticker · 016580 ISIN · KR7016580003 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2023-12-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 016580

About WHANIN PHARM CO.,LTD

https://www.whanin.com/?lang=eng

WHANIN PHARM CO.,LTD. is a pharmaceutical company that develops, manufactures, and sells a range of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), with a particular focus on neuropsychiatric treatments such as anti-psychotics and CNS stimulants. In addition to its core CNS portfolio, Whanin Pharm's product line includes pharmaceuticals for the cardiovascular and gastrointestinal systems, antibiotics, and vitamin supplements. The company also provides development and manufacturing services for finished drug formulations.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Hwanin Pharmaceutical. It details specific changes in share ownership by major shareholders (Lee Kwang-sik and Lee Won-bum) due to market purchases. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2023-12-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share transactions (purchases) made by an executive (Lee Kwang-sik) of Whanin Pharmaceutical. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports insider trading activities by company leadership.
2023-12-22 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Hwanin Pharmaceutical. It details specific share transactions (purchases) made by major shareholders (insiders/directors). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2023-12-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Lee Kwang-sik) of Whanin Pharmaceutical Co., Ltd. It details changes in share ownership due to market purchases. This type of filing is a standard regulatory disclosure for insider transactions, which corresponds to the 'Director's Dealing' category.
2023-12-13 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Whan In Pharm Co., Ltd. (환인제약(주)) for the third quarter of 2023. It contains detailed financial statements, management discussion and analysis, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Hwanin Pharmaceutical. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the third quarter of 2023 compared to previous periods. It is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q3 2023
2023-10-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.